Immunotherapy Firm’s Technology Demonstrates ‘Potential Use in Treating Cancers and Bacterial Infections’ – Streetwise Reports (registration)
|
Immunotherapy Firm's Technology Demonstrates 'Potential Use in Treating Cancers and Bacterial Infections'
Streetwise Reports (registration) The trial of Inovio's dMAb therapeutic against prostate-specific membrane antigen, the results of which were published in Cancer Immunology, Immunotherapy, showed "the construct produced monoclonal antibodies that controlled growth of human prostate … |
